Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G2A | P14555 | 15/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6333130 | 0.87 | PLA2G2A (0.55) | PLA2G2ARAB9A | |
| SCHEMBL6333002 | 0.83 | PLA2G2A (0.73) | PLA2G2A | |
| SCHEMBL6330547 | 0.83 | PLA2G2A (0.67) | PLA2G2APOLBKMT2A | |
| SCHEMBL6341055 | 0.81 | PLA2G2A (0.66) | PLA2G2ARAB9AMAPT | |
| SCHEMBL6334884 | 0.80 | PLA2G2A (0.66) | PLA2G2AMAPT | |
| SCHEMBL6339015 | 0.76 | PLA2G2A (0.67) | PLA2G2AMAPT | |
| SCHEMBL6339096 | 0.76 | PLA2G2A (0.72) | PLA2G2A | |
| SCHEMBL6340813 | 0.75 | PLA2G2A (0.68) | PLA2G2AMAPT | |
| SCHEMBL6332702 | 0.73 | PLA2G2A (0.39) | PLA2G2AMAPTMEN1KMT2A | |
| SCHEMBL6333369 | 0.71 | PLA2G2A (0.65) | PLA2G2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6974831-B2 | sPLA2 inhibitors | ELI LILLY AND COMPANY (US) | 2005-12-13 | — | — | US | disclosed |
| US-20040077704-A1 | Novel spla2 inhibitors | BEIGHT DOUGLAS WADE (US) | 2004-04-22 | — | — | US | disclosed |
| EP-1349834-A2 | CYCLOALKYFUSED [G]-INDOLE COMPOUNDS AS SPLA2-INHIBITORS IN THE TREATMENT OF INFLAMMATORY DISEASES | ELI LILLY AND COMPANY (US) | 2003-10-08 | — | — | EP | disclosed |
| WO-2002050030-A2 | CYCLOALKYLFUSED [G]-INDOLE COMPOUNDS AS SPLA2-INHIBITORS IN THE TREATMENT OF INFLAMMATORY DISEASES | ELI LILLY AND COMPANY (US) | 2002-06-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040077704-A1 | Novel spla2 inhibitors | PLAAT2, PLA2G12A, PLA2G4A | PLA2G2A 19/4885RAB9A 4252/4885CYP1A2 2474/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.